Safety of Ultrasound Contrast Agents in Pediatric Patients With Sickle Cell Disease and Trait.

Ultrasound contrast agent (UCA) use is increasing. Recent isolated reports observed a rise in pain-related adverse events with the intravenous administration of the UCA Definity in adults with sickle cell disease. To date, no studies have investigated the incidence of similar adverse events with UCA Lumason or Optison. We describe our experience regarding the safety of Lumason and Optison in children with sickle cell disease and trait who underwent contrast-enhanced ultrasound exams in our department with intravenous, intravesical, and other intracavitary routes. No pain-related or other adverse events were observed in this pediatric population with any route of UCA administration. © 2023 American Institute of Ultrasound in Medicine.

Citation

Aikaterini Ntoulia, Kassa Darge, Alexis A Thompson, Susan J Back. Safety of Ultrasound Contrast Agents in Pediatric Patients With Sickle Cell Disease and Trait. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2024 Jan;43(1):189-200

Mesh Tags

Substances

PMID: 37929626

search → result